{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-001194","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.367610+00:00","generated_at":"2026-05-16T10:33:07.760965+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TG Therapeutics prelim FY2025 global rev ~$616M; 2026 guided $875-900M","bullets":["Preliminary FY2025 total global revenue ~$616M; U.S. BRIUMVI net product rev Q4 ~$182M, FY ~$594M.","2026 target total global revenue $875-900M; U.S. BRIUMVI net product rev $825-850M.","2026 operating expense target ~$350M (excl. SBC) + ~$100M for subcutaneous BRIUMVI inventory build and secondary manufacturer start-up.","Pipeline milestones: ENHANCE IV BRIUMVI trial data mid-2026; subcutaneous BRIUMVI topline year-end 2026/1Q 2027; azer-cel Phase 1 data in Progressive MS H2 2026.","Plans to commence registration-directed trial for BRIUMVI outside MS and additional exploratory studies in autoimmune disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-001194","json":"https://secwatch.observer/filing/0001437749-26-001194.json","markdown":"https://secwatch.observer/filing/0001437749-26-001194.md","text":"https://secwatch.observer/filing/0001437749-26-001194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774926001194/0001437749-26-001194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774926001194/tgtx20260113_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:33:07.760965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}